Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
28 hedge funds and large institutions have $58.3M invested in Achilles Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
12% more funds holding
Funds holding: 25 → 28 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less capital invested
Capital invested by funds: $64.4M → $58.3M (-$6.07M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$936K |
| 2 |
KHCM
Kettle Hill Capital Management
New York
|
+$370K |
| 3 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
+$91.1K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$48.3K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
+$43.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$588K |
| 2 |
O
OrbiMed
New York
|
-$344K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$69K |
| 4 |
BlackRock
New York
|
-$20.6K |
| 5 |
Renaissance Technologies
New York
|
-$17.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CUAMC
26
China Universal Asset Management Company
Shanghai,
China
| $1K | +$1.04K | +366 | New |
|
|
WP
27
Woodline Partners
San Francisco,
California
| – | -$588K | -233,180 | Closed |
|
|
28
Citadel Advisors
Miami,
Florida
| – | -$69K | -27,468 | Closed |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$396 | +140 | New |
|
ACHL Hedge Fund Activity: Q3 2022 in Review
28 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q3 2022, worth a combined $58.3M — down 9.4% from $64.4M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ACHL positions and 2 closed out — a net gain of 3 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $936K. The largest seller was Woodline Partners, exiting entirely with an estimated $588K sold.
- 28 institutional investors held Achilles Therapeutics (ACHL) as of Q3 2022, up from 25 in Q2 2022.
- Funds reported $58.3M of Achilles Therapeutics stock for Q3 2022, down 9.4% quarter-over-quarter.
- 5 funds opened new Achilles Therapeutics positions in Q3 2022 and 2 closed out, a net change of +3 holders.
- The largest Achilles Therapeutics buyer in Q3 2022 was Point72 Asset Management, an estimated $936K added.
- The largest Achilles Therapeutics seller in Q3 2022 was Woodline Partners, an estimated $588K sold.
Based on aggregated 13F filings for Q3 2022.